On the stock market since 2003, it operates in the world of health and science. It has 3 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $6.1M a year. A small number, but proof the product has real buyers.
A loss of $13.8M against $6.1M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0003. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 12 months, executives reported 12 sells against just 3 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, BLMS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BLMS is a high-risk stock — not yet profitable, and its future rides on its product catching on.